Selected article for: "infectious virus and recombinant infectious virus"
Author: Dieterle, M. Eugenia; Haslwanter, Denise; Bortz, Robert H.; Wirchnianski, Ariel S.; Lasso, Gorka; Vergnolle, Olivia; Abbasi, Shawn A.; Fels, J. Maximilian; Laudermilch, Ethan; Florez, Catalina; Mengotto, Amanda; Kimmel, Duncan; Malonis, Ryan J.; Georgiev, George; Quiroz, Jose; Barnhill, Jason; Pirofski, Liise-anne; Daily, Johanna P.; Dye, John M.; Lai, Jonathan R.; Herbert, Andrew S.; Chandran, Kartik; Jangra, Rohit K.
Title: A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition
  • Cord-id: 41n1xrxq
  • Document date: 2020_7_3
    • ID: 41n1xrxq
    Snippet: Summary There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry
    Document: Summary There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein and show that this recombinant virus, rVSV-SARS-CoV-2 S, closely resembles SARS-CoV-2 in its entry-related properties. The neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S, and neutralization of rVSV-SARS-CoV-2 S and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is highly correlated. Our findings underscore the utility of rVSV-SARS-CoV-2 S for the development of spike-specific therapeutics and for mechanistic studies of viral entry and its inhibition.

    Search related documents:
    Co phrase search for related documents
    • access program and action mechanism: 1
    • access program and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acid dependent and action mechanism: 1
    • acid dependent and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • action mechanism and additional mutation: 1, 2
    • action mechanism and low expression: 1
    • action mechanism and lung adenocarcinoma: 1
    • acute respiratory syndrome and addgene plasmid: 1
    • acute respiratory syndrome and additional mutation: 1, 2, 3
    • acute respiratory syndrome and live memory: 1
    • acute respiratory syndrome and low expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
    • acute respiratory syndrome and low expression level: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lung adenocarcinoma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and lung adenocarcinoma cell: 1, 2, 3, 4
    • acute respiratory syndrome and lung ii pneumocyte: 1, 2
    • acute respiratory syndrome and lung ii pneumocyte type: 1, 2
    • acute respiratory syndrome and mabs neutralizing monoclonal antibody: 1